The latest price target for Pharvaris (NASDAQ:PHVS) was reported by Citizens Capital Markets on March 3, 2025. The analyst firm set a price target for $55.00 expecting PHVS to rise to within 12 months (a possible 242.68% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Pharvaris (NASDAQ:PHVS) was provided by Citizens Capital Markets, and Pharvaris reiterated their market outperform rating.

The last upgrade for Pharvaris NV happened on August 15, 2023 when Morgan Stanley raised their price target to $34. Morgan Stanley previously had an equal-weight for Pharvaris NV.

The last downgrade for Pharvaris NV happened on August 23, 2022 when Morgan Stanley changed their price target from $40 to $10 for Pharvaris NV.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pharvaris, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pharvaris was filed on March 3, 2025 so you should expect the next rating to be made available sometime around March 3, 2026.

While ratings are subjective and will change, the latest Pharvaris (PHVS) rating was a reiterated with a price target of $55.00 to $55.00. The current price Pharvaris (PHVS) is trading at is $16.05, which is out of the analyst’s predicted range.